The American opioid crisis has inspired a new generation of regenerative research. This includes exploring peptides for pain management. Due to their ability to grow muscles and tissues, the use of growth hormone releasing peptides (GHRPs) provides an effective alternative for managing chronic pain.
The study of synthetic growth hormones (HGHs) began in the 70s. Due to their anabolic properties, the World Anti-Doping Agency and most athletic programs banned HGHs in the 80s, and next-generation GHRPs remain banned in most competitive and professional sports. They’re viewed as a compound that provides an unfair competitive advantage in terms of increased strength and endurance.
Beyond their anabolic properties, peptides aid in muscle growth and cartilage, joint, ligament, tendon, and tissue regeneration. Although banned in athletics, their restorative benefits are effective for many patients recovering from accidents, injuries, and surgeries. Also, for retired athletes and anyone living with chronic pain caused by osteoarthritis, fibromyalgia, and other pain-inducing diagnoses.
Yes, the MHRA approved a limited range of peptide injections for therapeutic purposes. Research is underway in the UK and around the globe exploring the use of BPC157, TB500, CJC1295, and other GHRPs to reduce pain by promoting cartilage, joint, ligament, tendon, and tissue repair.
In addition to regeneration, some GHRPs decrease pain perception by modulating the transmission of tissue injury signals from pain neurons to the brain. When utilized to reduce pain signals, it’s often as part of a larger hormone therapy and treatment plan.
The objective of adding targeted peptide injections to treatment plans is to reduce the duration of opioid use, but peptides don’t replace opioids, especially post-injury. Research exploring how formulating drugs with peptides that target opioid receptors in the brain may create less addictive prescription pain relievers.
Where to Purchase Research-Grade Peptides for Pain Management in the UK
Reach out to Regen Labs to learn more about our options in research-approved peptides. Our products are not available for personal use.
Reach out to Regen Peptides to learn more about our options in research-approved peptides. . Our products are not available for personal use.
Regen Labs – Research Use Disclaimer
All products sold on www.regenlabs.co.uk or www.regenpeptides.co.uk are intended for laboratory research purposes only.
Regeneration Labs LTD does not endorse, encourage, or permit the use of any products for human consumption, therapeutic use, or diagnostic applications.
Our compounds are strictly supplied to qualified researchers and institutions for in vitro experimentation only.
By purchasing from www.regenlabs.co.uk or www.regenpeptides.co.uk, you confirm that you understand and agree to these terms.
The American opioid crisis has inspired a new generation of regenerative research. This includes exploring peptides for pain management. Due
Enter retatrutide (LY3437943), a novel triple hormone receptor agonist developed by Eli Lilly, targeting glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1
Key Points: Nicotinamide adenine dinucleotide (NAD+) is found in every cell, serving as an essential cofactor — the compounds necessary
What Are Your Mitochondria? Mitochondria are often called the “powerhouses” of your cells. These tiny, double-membraned organelles are responsible for
GLP-1 receptor agonists are peptides that have become a big focus in weight loss and metabolic health research. These compounds
